Quantcast

New Anti-Cancer Compound Shows Promise for Breast Cancer

July 9, 2013

Researchers from the Walter and Eliza Hall Institute in Melbourne, Australia, has discovered that anti-cancer compounds currently in clinical trials for some types of leukaemia could offer hope for treating the most common type of breast cancer. The anti-cancer compounds, called BH3-mimetics, were effective in treating aggressive oestrogen receptor-positive (ER-positive) breast cancers when combined with the breast cancer drug tamoxifen in preclinical models. Breast cancer researcher Professor Geoff Lindeman explains the research that he hopes will lead to clinical trials of BH3-mimetics for treating ER-positive breast cancers in the next few years.

Credit: Walter and Eliza Hall Institute of Medical Research



comments powered by Disqus